🚨 Breaking News in Bladder Cancer Research The IMvigor011 trial marks a major breakthrough in muscle-invasive bladder cancer (MIBC) care. For the first time, researchers demonstrated that circulating tumor DNA (ctDNA) testing with Signatera can predict which patients truly benefit from adjuvant immunotherapy after surgery. This is a game-changer for oncology — reducing overtreatment and ensuring personalized, precise cancer care. 🔍 Why IMvigor011 Matters for Bladder […]




